India Globalization Capital, Inc. (IGC) | Investment Case

1. Company Snapshot

1.a. Company Description

India Globalization Capital, Inc.purchases and resells physical infrastructure commodities.It operates through two segments, Infrastructure and Life Sciences.

The company rents heavy construction equipment, including motor grader and rollers; and undertakes highway construction contracts.It also develops cannabinoid-based products and therapies, such as hemp-based tinctures to treat anxiety, and enhance the lifestyle of patients suffering from Alzheimer's under the Hyalolex brand name; CBD based tinctures, capsules, and topical analgesic creams to treat pain under the Holief brand name; CBD powered beauty and skincare products under the Herbo brand name; and CBD infused beverages under the Sunday Seltzer brand.The company also engages in the wholesale of hemp extract under the Holi Hemp brand; production of products, such as lotions, creams, and oils, as well as white labeling support services; and extraction and distillation of crude oil into hemp extracts.

It operates in the United States, India, Colombia, and Hong Kong.The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

Show Full description

1.b. Last Insights on IGC

Recent news suggests that India Globalization Capital, Inc. (IGC) has been making significant progress in its Alzheimer's pipeline, with notable advancements in its Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer's dementia. The company has also announced the publication of an IMS Spotlight interview highlighting its strategic expansion into metabolic and neurological markets. However, there is no recent earnings release provided in the given data.

1.c. Company Highlights

Last Price	0.3
Change Percentage	-2.71%
Open	0.31
Previous Close	0.31
Market Cap ( Millions)	25
Volume	363469
Year High	0.5
Year Low	0.25
M A 50	0.38
M A 200	0.34

FCF Yield	-22.79%
Dividend Yield	0.00%
ROE	-96.36%
Debt / Equity	1.69%
Net Debt / EBIDTA	12.67%
Price To Book	3.33
Price Earnings Ratio	-4.18
Price To FCF	-4.39
Price To sales	22.91
EV / EBITDA	-3.19

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

Dec -02

Source: accessnewswire.com

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

Nov -25

Source: accessnewswire.com

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

Nov -17

Source: accessnewswire.com

IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates

Nov -14

Source: zacks.com

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

Nov -13

Source: accessnewswire.com

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

Nov -10

Source: accessnewswire.com

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

Nov -03

Source: accessnewswire.com

All You Need to Know About IGC Pharma, Inc. (IGC) Rating Upgrade to Strong Buy

Oct -24

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (25.90%)

6. Segments

Life Sciences

Expected Growth: 25.9%

Growing demand for cannabinoid-based therapies, increasing prevalence of rare diseases, and opioid epidemic drive growth. India Globalization Capital's focus on developing innovative treatments positions it for success in this expanding market.

Infrastructure

Expected Growth: 12.3%

India's growing population, urbanization, and government initiatives like 'Smart Cities' and 'Housing for All' drive demand for infrastructure development, positioning India Globalization Capital, Inc.'s infrastructure segment for growth.

7. Detailed Products

Hyalolex

A patented, plant-based cannabinoid product for the treatment of Alzheimer's disease

Natasha

A line of CBD-based products for the treatment of pain, anxiety, and sleep disorders

Sativum

A line of CBD-based products for the treatment of skin care and beauty

Data Analytics

Data analytics services for the cannabis industry

Blockchain-based Supply Chain Management

A blockchain-based platform for tracking and verifying cannabis products

8. India Globalization Capital, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for India Globalization Capital, Inc. is medium due to the presence of alternative investment options for investors.

Bargaining Power Of Customers

The bargaining power of customers for India Globalization Capital, Inc. is low due to the company's diversified investment portfolio and lack of dependence on a single customer.

Bargaining Power Of Suppliers

The bargaining power of suppliers for India Globalization Capital, Inc. is medium due to the company's reliance on a few key suppliers for its investment activities.

Threat Of New Entrants

The threat of new entrants for India Globalization Capital, Inc. is high due to the relatively low barriers to entry in the investment management industry.

Intensity Of Rivalry

The intensity of rivalry for India Globalization Capital, Inc. is high due to the presence of several established players in the investment management industry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	3.12%
Debt Cost	3.95%
Equity Weight	96.88%
Equity Cost	12.11%
WACC	11.85%
Leverage	3.23%

11. Quality Control: India Globalization Capital, Inc. passed 4 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

RCM Technologies

A-Score: 5.5/10

Value: 5.1

Growth: 8.4

Quality: 5.3

Yield: 0.0

Momentum: 9.0

Volatility: 5.0

1-Year Total Return ->

Tejon Ranch

A-Score: 4.5/10

Value: 7.8

Growth: 2.9

Quality: 3.6

Yield: 0.0

Momentum: 4.0

Volatility: 8.7

1-Year Total Return ->

India Globalization Capital

A-Score: 4.1/10

Value: 6.2

Growth: 5.1

Quality: 4.2

Yield: 0.0

Momentum: 6.5

Volatility: 2.7

1-Year Total Return ->

FTAI Infrastructure

A-Score: 3.5/10

Value: 7.2

Growth: 4.2

Quality: 2.4

Yield: 4.0

Momentum: 1.0

Volatility: 2.3

1-Year Total Return ->

Mammoth Energy Services

A-Score: 3.3/10

Value: 9.4

Growth: 3.7

Quality: 3.2

Yield: 0.0

Momentum: 0.5

Volatility: 3.0

1-Year Total Return ->

A-Score: 2.4/10

Value: 7.7

Growth: 1.6

Quality: 2.1

Yield: 0.0

Momentum: 1.0

Volatility: 2.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

22.57%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

11.85%

India Globalization Capital, Inc. - US45408X3089

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on IGC

1.c. Company Highlights

Lower Growth

More Volatile

Average Quality

Earnings Miss

Revenues Beats

Average Yield

Stable Momentum

Earnings Beats

Revenues Miss

Medium Volatility

Weak Momentum

Average Growth

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (25.90%)

6. Segments

Life Sciences

Expected Growth: 25.9%

Infrastructure

Expected Growth: 12.3%

7. Detailed Products

Hyalolex

Natasha

Sativum

Data Analytics

Blockchain-based Supply Chain Management

8. India Globalization Capital, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: India Globalization Capital, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.3$

Current Price

0.3$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA